1Sageda S, Nordal KP, Hartmann A, et al.The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients [J]. American Journal of Transplantation. 2002; 2 (9): 850-6.
2Geist LJ, Dai LY. Immediate early gene 2 of human cytomegalovirus increases interteukin 2 receptor- [ alpha ] gene expression[J]. J Invest Med 2000; 48: 60-65.
3Nieto FJ. Viruses and athercsclerosis: a critical review of the epidemiologic evidence[J]. Am Heart J 1999; 138 (Suppl):S453-S460.
4Streblow DN. Soderberg-Naucler C. Vieira J. et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration[ J ]. cell 1999; 99: 511-520.
5Jeejeebhoy FM. Zaltanan JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient:A new treatment strateg[ J ]. Transplantation 1998; 65: 1645-1648.
6Pouria S, State OI, Wong W, et al. CMV infection is associated with transplant renal artery stenosis [J]. QJM 1998; 91: 185-189.
7Birk PE, Chavers BM. Does cytomegalovirus cause glomendar injury in renal allograft recipients [J]. J Am Soc Nephrol 1997;8: 1801-1808.
8Schnitzler MA, Woodward RS, Brennan DC, et al. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation:Implications for organ allocation :Implications for organ allocation[ J]. Am J Kidney Dis 1997; 29: 428-434.
10Middeldorp JM, Sillekens P,Lunenberg J.Diagnosis of active HCMV infection: the mRNA approach [ J ]. Organs and Tissues 2000; 3: 99-107.
同被引文献39
1Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients[J]. Am J Transplant,2009,9 (4): 78-86.
2De Keyzer K, Van Laecke S, Peeters P, et al. Human cytomegalovirus and kidney transplantation: a clinician’s update[J]. Am J Kidney Dis, 2011, 58(1): 118-126.
4Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation[J]. Transpl Infect Dis, 2010, 12(5): 397-405.
5Tian JH, Wang X, Yang KH, et al. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials[J]. Transplant Proc, 2009 , 41(9): 3671-3676.
6Prichard MN, Kern ER. The search for new therapies for human cytomegalovirus infections[J]. Virus Res, 2011, 157(2): 212-221.
7Crough T, Khanna R. Immunobiology of human cytomegalovi-rus: from bench to bedside[J]. Clin Microbiol Rev, 2009, 2(1): 76-98.
8Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and epstein-barr virus infections[J]. Herpes, 2003, 10(3): 60-65.
9Dzabic M, Rahbar A, Yaiw KC, et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival[J]. Clin Infect Dis, 2011, 53(10): 969-976.
10Helanter? I, Loqinov R, Koskinen P, et al. Persistent cytomegalovirus infection is associated with increased expression of TGF-b 1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts[J]. Nephrol Dial Transplant, 2005, 20(4): 790-796.
